Rocket Pharmaceuticals' shares rallied ahead of the opening bell after the Food and Drug Administration lifted its clinical hold on the biotechnology company's Phase 2 trial of its RP-A501 treatment ...

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) jumped 23% after the U.S. Food and Drug Administration lifted the ...

Celldex Therapeutics (CLDX) slipped in premarket trading on Wednesday after releasing results from its Phase 2 study of ...

The MTA board approved an approximately $2 billion tunnel boring contract for the Second Avenue Subway line expansion in ...

Celldex Therapeutics Inc. will not advance barzolvolimab (CDX-0159, barzo) in eosinophilic esophagitis (EoE) after taking a ...

With approval to proceed, the Phase II trial (NCT06092034) of RP-A501 for Danon disease restarts under an optimized dosing and immunomodulatory strategy.

In late May, a patient died after receiving Rocket Pharmaceuticals' investigational gene therapy for Danon disease, spurring ...

SELLAS Life Sciences is developing GPS as a WT1 immunotherapy, which is in Phase 3 for AML. Click here to read why SLS stock ...

Alto Neuroscience Inc. (NYSE: ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The MTA has relaunched its Customer Ambassador Program on Monday, Aug 18, continuing the largest customer outreach program in ...

The Chennai Metro Rail Limited (CMRL) has begun safety certification trials on its Phase 2 network, with tests now underway ...